Proteomics appoints medical devices sales agency for Europe
Filed with ASX · · 3 pages · English
Proteomics International Laboratories Ltd. on 6ix
Earlier from Proteomics International Laboratories
- March 2024 Quarterly Activities Report and Appendix 4C
- Proteomics signs with Oxford Univ to validate test for Endo
- PromarkerD US commercialisation & Promarker pipeline update
- European patent granted for OxiDx technology
- Study validates biomarkers for oesophageal cancer blood test
Later from Proteomics International Laboratories
- Eurobio Scientific to sell PromarkerD DKD test in France
- June 2024 Quarterly Activities Report and Appendix 4C
- Groundbreaking results for type 1 diabetes and kidney health
- Update on commercialisation of PromarkerD in the USA
- Esophageal cancer diagnostic delivers excellent results
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories